AR083017A1 - Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol - Google Patents
Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanolInfo
- Publication number
- AR083017A1 AR083017A1 ARP110103389A ARP110103389A AR083017A1 AR 083017 A1 AR083017 A1 AR 083017A1 AR P110103389 A ARP110103389 A AR P110103389A AR P110103389 A ARP110103389 A AR P110103389A AR 083017 A1 AR083017 A1 AR 083017A1
- Authority
- AR
- Argentina
- Prior art keywords
- etil
- productions
- imidazol
- methylphenyl
- methanol
- Prior art date
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 title 3
- 150000002148 esters Chemical class 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas y usos.Reivindicación 1: Un compuesto de la fórmula (1), sus enantiómeros individuales, sus diastereoisómeros, sus hidratos, sus solvatos, sus formas de cristal, sus isómeros individuales, sus tautómeros individuales o una sal farmacéuticamente aceptable de la misma, en la que R1 es H o alquil C1-3; R2 es H o alquil C1-3; R3 es H, alquil C1-10, heterociclo o aril; y R es alquil C1-10, heterociclo o aril.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38337010P | 2010-09-16 | 2010-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083017A1 true AR083017A1 (es) | 2013-01-23 |
Family
ID=44675870
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103390A AR083018A1 (es) | 2010-09-16 | 2011-09-16 | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden |
| ARP110103391A AR083019A1 (es) | 2010-09-16 | 2011-09-16 | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden |
| ARP110103389A AR083017A1 (es) | 2010-09-16 | 2011-09-16 | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol |
| ARP110103392A AR083020A1 (es) | 2010-09-16 | 2011-09-16 | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103390A AR083018A1 (es) | 2010-09-16 | 2011-09-16 | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden |
| ARP110103391A AR083019A1 (es) | 2010-09-16 | 2011-09-16 | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103392A AR083020A1 (es) | 2010-09-16 | 2011-09-16 | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US8492422B2 (es) |
| EP (13) | EP3053576B1 (es) |
| JP (4) | JP6073229B2 (es) |
| KR (7) | KR20140005154A (es) |
| CN (5) | CN103209694A (es) |
| AR (4) | AR083018A1 (es) |
| AU (4) | AU2011301856C1 (es) |
| BR (4) | BR112013006352A2 (es) |
| CA (8) | CA2812191C (es) |
| CL (4) | CL2013000733A1 (es) |
| CY (3) | CY1121024T1 (es) |
| DK (9) | DK3338777T3 (es) |
| ES (10) | ES2760920T3 (es) |
| HU (5) | HUE047476T2 (es) |
| IL (4) | IL225280A0 (es) |
| MX (4) | MX2013003009A (es) |
| MY (4) | MY161607A (es) |
| NZ (1) | NZ608751A (es) |
| PL (7) | PL3050563T3 (es) |
| PT (7) | PT3053576T (es) |
| RU (4) | RU2612351C2 (es) |
| SG (4) | SG188573A1 (es) |
| SI (5) | SI3050563T1 (es) |
| TR (1) | TR201909249T4 (es) |
| TW (4) | TWI591058B (es) |
| UA (1) | UA112973C2 (es) |
| WO (4) | WO2012037453A1 (es) |
| ZA (4) | ZA201302194B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3566703T3 (da) * | 2009-02-13 | 2021-07-05 | Allergan Inc | Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| MX2014000871A (es) * | 2011-07-22 | 2014-06-23 | Allergan Inc | Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo. |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| USD794650S1 (en) | 2014-11-28 | 2017-08-15 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with a graphical user interface |
| CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
| KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| US20240287093A1 (en) * | 2018-08-24 | 2024-08-29 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| WO2022221071A1 (en) * | 2021-04-16 | 2022-10-20 | Ads Therapeutics Llc | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs |
| KR20250141793A (ko) * | 2023-02-08 | 2025-09-29 | 보슈 롬 아일랜드 리미티드 | 시력을 개선시키기 위한 알파-2-아드레날린성 효능제 |
| WO2025179071A1 (en) * | 2024-02-20 | 2025-08-28 | Bausch + Lomb Ireland Limited | Sustained-release drug delivery compositions for treating ocular diseases |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0642332B1 (en) | 1992-05-13 | 1997-01-15 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| ES2188649T3 (es) | 1993-11-15 | 2003-07-01 | Schering Corp | Fenil-alquil-imidazoles como antagonistas del receptor h3. |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| EA010392B1 (ru) * | 2003-05-27 | 2008-08-29 | Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) | Производные имидазолов, способ их получения и их применение в качестве лекарственного средства |
| KR20060052809A (ko) * | 2003-07-14 | 2006-05-19 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 프로젝션 디바이스 |
| JP5165242B2 (ja) | 2003-09-12 | 2013-03-21 | アラーガン、インコーポレイテッド | 疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物 |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| CN104490884A (zh) | 2004-05-25 | 2015-04-08 | 桑斯罗萨医药发展公司 | 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 |
| US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| WO2006036480A1 (en) * | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| EP2393800B1 (en) | 2009-02-06 | 2014-10-08 | Allergan, Inc. | Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors |
| DK3566703T3 (da) * | 2009-02-13 | 2021-07-05 | Allergan Inc | Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
-
2011
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
-
2013
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
-
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
-
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
-
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
-
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| CO6251287A2 (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato -842 | |
| AR056764A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
| AR083026A1 (es) | Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon | |
| AR084001A1 (es) | Monobactamas y su uso en el tratamiento de infecciones bacterianas | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| CO6241121A2 (es) | Derivados de azapeptidps | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| AR061980A1 (es) | Acilanilidas sustituidas y metodos para su utilizacion | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| NO20091858L (no) | Hydrobenzamid derivater som inhibitorer av HSP90 | |
| CR11483A (es) | Inhibidores de peptido desformilasa | |
| AR060838A1 (es) | Formulaciones de dosificacion solida | |
| AR088246A1 (es) | Derivados de etinilo | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |